Alnylam Pharmaceuticals Inc.

Sector and Industry

Healthcare, Biopharmaceuticals

Performance (1Y)

13.25%

Market Cap

31.82 Bil.

P/E Ratio

170.70

Dividend Yield

0.00 %

Earnings per Share

2.06 €

Peer Group

Company NameMarket CapRevenue Last Reported YearP/E RatioProfit Growth 1YLast PricePrevious Trading Day Change
Eli Lilly and Company864.54 Bil.57.78 Bil.46.82
+86.88 %
0.00
-
Johnson & Johnson425.70 Bil.83.48 Bil.18.82
+82.71 %
0.00
-
AbbVie Inc.343.94 Bil.54.21 Bil.96.78
-5.29 %
0.00
-
Roche Holding AG286.62 Bil.65.80 Bil.20.72
+58.45 %
0.00
-
AstraZeneca PLC244.91 Bil.52.09 Bil.27.55
+39.41 %
0.00
-
NOVARTIS AG 224.76 Bil.48.44 Bil.18.30
+12.45 %
0.00
-
Merck & Co. Inc.221.79 Bil.57.55 Bil.14.46
+2.25 %
0.00
-
Novo-Nordisk AS B193.52 Bil.41.49 Bil.14.11
+1.54 %
0.00
-
Amgen Inc.150.16 Bil.32.57 Bil.23.01
+80.77 %
0.00
-
Gilead Sciences Inc.129.70 Bil.26.10 Bil.18.10
+1,599.93 %
0.00
-

Facts & figures

Price data

TRADE PLATFORMBörse Stuttgart (XSTU)
LAST PRICE237.5 G0 Units
PRICE DETERMINATION TIME07/21/2026 / 09:56:30 PM
DAILY VOLUME (UNITS)40
DAILY HIGH / LOW243236.6
PREV. DAY'S PRICE238.3 (07/20)
CHANGE DAY BEFORE
-0.80
-0.34 %
52 WEEK HIGH / LOW418.8 (10/21)232.9 (07/20)
More Price Information

Key Figures (in EUR)

2023202420252026e2027e
EARNINGS PER SHARE
-3.26-2.012.066.159.61
DIVIDENDS PER SHARE
0.000.000.000.000.00
DIVIDEND YIELD IN %
0.00 %0.00 %0.00 %--
DIVIDEND GROWTH IN %
-----
PRICE - EARNINGS RATIO
--170.7037.9924.34
PRICE - BOOK RATIO
-453.5066.70--
PRICE - SALES RATIO
13.0813.3614.42--
PRICE - CASH FLOW RATIO
229.54-102.19--
Further Key Figures

Master Data

WKN
A0CBCK
ISIN
US02043Q1076
SYMBOL
DUL
EXCHANGE SEGMENT
Freiverkehr
TYPE OF FINANCIAL INSTRUMENT
Equity
DENOMINATION
Alnylam Pharmaceuticals
INDEX MEMBERSHIP
-
TRADING SEGMENT
-
TRADING HOURS
07:30:00 AM - 10:00:00 PM
TRADING CURRENCY
Euro
NOMINAL CURRENCY
US Dollar
SETTLEMENT CURRENCY
Euro
SECTOR AND INDUSTRYHealthcare, Biopharmaceuticals
NUMBER OF SHARES
133.51 Mil.
MARKET CAPITALISATION
31.82 Bil.

Performance overview

1W1M3M6M1Y3Y5YYTD
PERFORMANCE
-6.22 %
-0.75 %
-9.43 %
-21.22 %
-13.25 %
30.50 %
60.69 %
-29.46 %
HIGH252.60335.40335.40335.40418.80418.80418.80363.20
LOW232.90232.90232.90232.90232.90131.55112.80232.90

Dividende

pro Aktie
Alnylam Pharmaceuticals does not deliver dividend information

Company profile

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002, and is headquartered in Cambridge, MA.

Shareholder Structure (Top 10)

AnteilName
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available

Analyst Rating

Ø-Target Price DistanceNot Available
Current Price
Not Available
Ø-Target Price
Not Available
Average ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0

Company Events

No company events available.